ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)

Adverse Events Definitions
**ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)**

**Device Malfunction**

Device malfunction denotes a failure of one or more of the components of the MCSD system which either directly causes or could potentially induce a state of inadequate circulatory support (low cardiac output state) or death. A failure that was iatrogenic or recipient-induced will be classified as an Iatrogenic/Recipient-Induced Failure.

Device failure should be classified according to which components fails as follows:

1. **Pump** failure (blood contacting components of pump and any motor or other pump actuating mechanism that is housed with the blood contacting components). In the special situation of **pump thrombosis**, thrombus is documented to be present within the device or its conduits that result in or could potentially induce circulatory failure.

2. **Non-pump** failure (e.g., external pneumatic drive unit, electric power supply unit, batteries, controller, interconnect cable, compliance chamber)

**Major Infection**

A clinical infection accompanied by pain, fever, drainage and/or leukocytosis that is treated by antimicrobial agents (non-prophylactic). A positive culture from the infected site or organ should be present unless strong clinical evidence indicates the need for treatment despite negative cultures. The general categories of infection are listed below:

- **Localized Non-Device Infection**
  Infection localized to any organ system or region (e.g. mediastinitis) without evidence of systemic involvement (See sepsis definition), ascertained by standard clinical methods and either associated with evidence of bacterial, viral, fungal or protozoal infection, and/or requiring empirical treatment.

- **Percutaneous Site and/or Pocket Infection**
  A positive culture from the skin and/or tissue surrounding the drive line or from the tissue surrounding the external housing of a pump implanted within the body, coupled with the need to treat with antimicrobial therapy when there is clinical evidence of infection such as pain, fever, drainage, or leukocytosis.

- **Internal Pump Component, Inflow or Outflow Tract Infection**
  Infection of blood-contacting surfaces of the LVAD documented by positive site culture. (There should be a separate data field for paracorporeal pump that describes infection at the percutaneous cannula site, e.g. Thoratec PVAD).

- **Sepsis**
  Evidence of systemic involvement by infection, manifested by positive blood cultures and/or hypotension.
Neurological Dysfunction

Any new, temporary or permanent, focal or global neurological deficit ascertained by a standard neurological examination (administered by a neurologist or other qualified physician and documented with appropriate diagnostic tests and consultation note). The examining physician will distinguish between a transient ischemic attack (TIA), which is fully reversible within 24 hours (and without evidence of infarction), and a stroke, which lasts longer than 24 hours (or less than 24 hours if there is evidence of infarction). Each neurological event must be subcategorized as:

1) Transient Ischemic Attack (acute event that resolves completely within 24 hours with no evidence of infarction)
2) Ischemic or Hemorrhagic Cardiovascular Accident/CVA (event that persists beyond 24 hours or less than 24 hours associated with infarction on an imaging study.)

In addition, to above, for patients < 6 months of age, any of the following:

3) New abnormality of head ultrasound
4) EEG positive for seizure activity with or without clinical seizure

Bleeding

An episode of SUSPECTED INTERNAL OR EXTERNAL BLEEDING that results in one or more of the following:
- a. Death,
- b. Re-operation,
- c. Hospitalization,
- d. Transfusion of red blood cells as follows:

If transfusion is selected, then apply the following rules:

During first 7 days post implant
- Adults (≥ 50 kg): ≥ 4U packed red blood cells (PRBC) within any 24 hour period during first 7 days post implant.
- Pediatrics (< 50 kg): ≥ 20 cc/kg packed red blood cells (PRBC) within any 24 hour period during first 7 days post implant.

After 7 days post implant
- Any transfusion of packed red blood cells (PRBC) after 7 days following implant with the investigator recording the number of units given. (Record number of units given per 24 period).

Note: Hemorrhagic stroke is considered a neurological event and not as a separate bleeding event.
Respiratory Failure

Impairment of respiratory function requiring reintubation, tracheostomy or (for patients older than age 5 years) the inability to discontinue ventilatory support within six days (144 hours) post-VAD implant. This excludes intubation for re-operation or temporary intubation for diagnostic or therapeutic procedures.

Arterial Non-CNS Thromboembolic Event

An acute systemic arterial perfusion deficit in any non-cerebrovascular organ system due to thromboembolism confirmed by one or more of the following:

1) standard clinical and laboratory testing
2) operative findings
3) autopsy findings

This definition excludes neurological events.

Right Heart Failure

Symptoms and signs of persistent right ventricular dysfunction [central venous pressure (CVP) > 18 mmHg with a cardiac index <2.3 L/min/m2 in the absence of elevated left atrial/pulmonary capillary wedge pressure (greater than 18 mmhg), tamponade, ventricular arrhythmias or pneumothorax] requiring RVAD; implantation; or requiring inhaled nitric oxide or inotropic therapy for a duration of more than 1 week at any time after LVAD implantation.”